Alzforum

Trusted

http://www.alzforum.org/

Last activity: 27.10.2026

Active

Categories: ContentFanInformationITNewsPageProductResearchServiceWebsite

Alzforum is a dynamic web-based scientific community dedicated to understanding Alzheimer's disease and related disorders. Our writers report about the latest scientific findings on Alzheimer’s, host live webinars on pressing issues, and cover conferences all over the world. Alzforum also maintains databases of Alzheimer's risk genes, current research models, reagents, therapeutics, and more. Check our website daily to find out what's new.

Commenting Guidelines

Thank you for visiting Alzforum's Fan Page on Facebook, intended to keep you posted on the latest in Alzheimer research news. Please feel free to comment on news content posted here. Just keep in mind the following:

Keep it on topic and keep it clean (please, no abusive, defamatory, offensive, or profane comments). We may, in our sole discretion, remove comments or fans for a variety of reasons.

Opinions, statements, or views posted by fans on this Page are communications by the persons posting them, and they are not adopted or endorsed by Alzforum and do not represent the views of Alzforum or its management.

Disclaimer

Alzforum is not affiliated with Facebook, Inc. or the Facebook, Inc. service. Alzforum does not expressly or implicitly adopt or endorse any of the expressions, opinions or content posted by fans or any third-parties on our Facebook Fan Page. Alzforum does not control, serve, adopt or endorse any advertising, messages or content that Facebook may publish on its site or on the Alzforum Fan Page. Alzforum does not adopt or endorse any products, services, advertisements, recommendations or statements, or any other content that may appear on Facebook or on other Facebook-affiliated sites. No part of this page is intended to diagnose disease or give medical advice.

Twitter Facebook LinkedIn Email

Likes

1.14K

Followers

9.52K

Followers

1.16K

Website visits

126.4K /mo.

Mentions

Overview

Location

United States, Massachusetts, Cambridge

Employees

11-50

Founded date

1996

Mentions in press and media 27

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Jul 20, 2026	Cortisol Blocker Earns Peer Review: Depression Drug Active Weeks After Stopping	By Jackie Manning Published: Jul 20 2026, 4:47 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
Jul 20, 2026	Cyclops Came From Fossil Skulls: Science Behind Nolan’s $264M Odyssey Opening	By Maxwell Templeton Published: Jul 20 2026, 3:43 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
Jul 15, 2026	Alzheimer’s Drug Kisunla Cuts ARIA Risk Nearly in Half, Two-Year Benefit Holds	By Keith Benitez Published: Jul 15 2026, 12:10 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
Jul 13, 2026	Alzheimer’s Protein Builds Long-Term Memories: Blanket Suppression May Backfire	By Adrian Parham Published: Jul 13 2026, 5:42 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
Jul 13, 2026	Cholesterol Drug Cuts Alzheimer’s Biomarker in Most At-Risk Gene Carriers	By Clark Johnson Published: Jul 13 2026, 4:52 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard
Oct 21, 2024	Идет расследование беспрецедентного по масштабам подлога в исследованиях нейродегенерации	Падение на дно профессиональной этики титана исследований в области нейродегенерации шокировало научное сообщество. Невропатолог Элиезер Маслия, автор более чем 800 научных статей, специалист с мировым именем в изучении α ‑синуклеина (белка...
Feb 20, 2024	Health \| Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefit	Melody Petersen \| Los Angeles Times (TNS) In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to includ...
Aug 28, 2023	Specialised Therapeutics acquires commercialisation rights to new oral MND therapy	.. ST to partner with Dutch biotech company Treeway BV .. First CNS therapy in ST therapeutic portfolio SINGAPORE, Aug. 28, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner w...
Jul 7, 2023	FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease	/EIN News/ -- The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease The Centers for Medicare & Medicaid Services (CMS) annou...
Jul 6, 2023	Eisai Alzheimer’s Drug Wins Full FDA Approval, But With Sterner Safety Alert	Eisai has won full FDA approval for its Alzheimer’s disease drug, a regulatory decision that sets precedent for the review and potential approval of other therapies for the neurodegenerative disorder. However, while conversion of Leqembi’s ...
Jun 9, 2023	FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease	/EIN News/ -- Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for tr...
May 17, 2023	Understanding the Latest Advances in Alzheimer’s Diagnostics	Alzheimer’s Diagnostics: Advancing the State of the Art Understanding the Latest Advances in Alzheimer’s Diagnostics This iSelect Deep Dive offers valuable insights into cutting-edge research on Alzheimer’s diagnostics. The discussion cover...
Jan 7, 2023	Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease	Submission for traditional approval follows FDA accelerated approval of LEQEMBI on the same day, and is based on data from the confirmatory Phase 3 Clarity AD clinical trial TOKYO and CAMBRIDGE, Mass., Jan. 6, 2023 /PRNewswire/ -- Eisai Co....
Sep 29, 2022	Promising data from large Alzheimer’s study bodes well for this Seattle startup	AltPep CEO and founder Valerie Daggett. (AltPep Photo) Alzheimer’s disease researchers were buoyed by positive data released Tuesday from a large clinical trial of an experimental therapy being developed by Biogen and Eisai. The early data ...
Jul 27, 2022	Potential Research Fabrication Bombshell Threatens Amyloid Theory of Alzheimer’s Disease	Alzheimer’s disease is a form of progressive dementia that we’ve labored to figure out for decades. Scientists made some headway with the amyloid hypothesis of Alzheimer’s disease, but progress is slow, and the hypothesis is incomplete. Now...
Jun 17, 2022	New Alzheimer's Drug Delivers Disappointing Results	FRIDAY, June 17, 2022 (HealthDay News) -- An experimental Alzheimer's drug called crenezumab did not prevent or slow mental decline in patients with a genetic mutation that greatly raises the risk of developing the disease, the results...
Jun 17, 2022	New Alzheimer Disease Drug Delivers Disappointing Results	FRIDAY, June 17, 2022 (HealthDay News) -- An experimental drug for Alzheimer disease called crenezumab did not prevent or slow mental decline in patients with a genetic mutation that greatly raises the risk for developing the disease, the r...
Aug 5, 2021	Aduhelm approval sparks HHS watchdog review of FDA’s accelerated approval pathway	The Department of Health and Human Services (HHS) Office of the Inspector General will review the FDA’s accelerated approval pathway, the office announced Wednesday. This sweeping review comes just two months after the controversial approva...
Apr 16, 2019	The trouble with mice as behavioral models for Alzheimer’s and other neurologic diseases	There’s been a lot of talk about overinvestment in interventions aimed at amyloid in the weeks since Biogen discontinued a late-stage study of aducanumab, an experimental therapy for Alzheimer’s disease. Although much of the focus has been ...
Feb 14, 2018	The search for new Alzheimer's treatments just faced another setback - here's where researchers are looking now	AP/Alastair Grant Advertisement It's been a while since we've had good news in search for new Alzheimer's drugs. On Tuesday, Merck said it was discontinuing one of its remaining trials that was looking at using the treatment ...
Jul 31, 2013	Why Deborah Dunsire’s Unusual Bet on Alzheimer’s Makes Sense	Share Share on Facebook Share on Twitter LinkedIn Email Reprints Just because a biotech company has landed a high-profile chief executive, does that mean its product is going to work? I’ve been asking myself that question in the wake of the...
Apr 9, 2012	Biotechnology company acquires license for Alzheimer’s disease vaccine	The move comes as the latest expansion of its vaccine portfolio. Last month, it acquired the license for technology and product rights for a hepatitis B virus vaccine in the preclinical phase of development called Chimigen from Akshaya Bio....
	Years of Alzheimer's research were based on a key finding. Now an investigation alleges it was faked, and the work may have been wasted.	A person doing Alzheimer's disease research (stock image). Tek Image/Science Photo Library/Getty Images Redeem now Results of a seminal 2006 Alzheimer's paper appear fabricated, an investigation said. More than 2,200 later studies...
	Biotechnology company acquires license for Alzheimer’s disease vaccine	A company has acquired a DNA vaccine for Alzheimer’s disease that is designed to trigger an immune response to the disease. The vaccine, in preclinical development, differs from other Alzheimer’s vaccines under study in that it only contain...
	Какие области медицины интересны для инвестирования	Биотехнологии и фармацевтические разработки – основа современной инновационной медицины. Биотехнологические венчурные капиталисты имеют более высокую чистую внутреннюю норму доходности, чем венчурные фонды других отраслей (26,8% против 21,8...
	A neuroscientist shares the 4 brain-changing benefits of exercise—and how much she does every week	When we think about the benefits of exercise, we usually think of better sleep, more energy, maintaining a healthy weight, stronger muscles or a healthier heart. These are all true. But we rarely consider the immediate effects that physical...

Reviews 0

FAQ about Alzforum

When was Alzforum founded?

Alzforum was founded in 1996.

What has the press written about Alzforum?

Parsers VC has collected 27 articles mentioning Alzforum, among them “Cortisol Blocker Earns Peer Review: Depression Drug Active Weeks After Stopping” (Jul 20, 2026) and “Cyclops Came From Fossil Skulls: Science Behind Nolan’s $264M Odyssey Opening” (Jul 20, 2026).

Is Alzforum still active?

Yes, Alzforum is active; its latest activity on Parsers VC dates from Oct 27, 2026.